OB_Kertorolac(Toradol)

OB_Kertorolac(Toradol) - Kertorolac(Toradol Routine use...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Kertorolac/(Toradol) Routine use: Short-term management of pain Oral therapy is indicated only as a continuation of parenteral therapy; parenteral therapy should not exceed 20 doses/5 days. Total duration of therapy by all routes should not exceed 5 days. PO (Adults <65 yr): 20 mg initially, followed by 10 mg q 4-6 hr as needed (not to exceed 40 mg/day). PO (Adults ≥65 yr, <50 kg, or with renal impairment): 10 mg q 4-6 hr as needed (not to exceed 40 mg/day). IM (Adults <65 yr): Single dose --60 mg. Multiple dosing --30 mg q 6 hr (not to exceed 120 mg/day). IM (Adults ≥65 yr, <50 kg, or with renal impairment): Single dose --30 mg. Multiple dosing --15 mg q 6 hr (not to exceed 60 mg/day). IV (Adults <65 yr): Single dose --30 mg. Multiple dosing --30 mg q 6 hr (not to exceed 120 mg/day). IV (Adults ≥65 yr, <50 kg, or with renal impairment): Single dose --15 mg. Multiple dosing --15 mg q 6 hr (not to exceed 60 mg/day). C- Therapeutic: nonsteroidal anti-inflammatory agents, nonopioid analgesics Pharmacologic: pyrroziline carboxylic acid A- Inhibits prostaglandin synthesis, producing peripherally mediated analgesia. Also has antipyretic and anti-inflammatory properties.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

Page1 / 3

OB_Kertorolac(Toradol) - Kertorolac(Toradol Routine use...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online